Abbott Laboratories Gets Emergency Use Authorization for Covid-19/Flu Test
By Chris Wack
Abbott Laboratories said the U.S. Food and Drug Administration
granted Emergency Use Authorization for its Alinity m Resp-4-Plex
molecular assay to detect and differentiate SARS-CoV-2, influenza
A, influenza B and respiratory syncytial virus in one test.
The company said the Alinity m Resp-4-Plex test can be conducted
with one swab specimen self-collected at a healthcare location from
individuals suspected by their provider of respiratory viral
infection consistent with Covid-19.
Abbott said it has accelerated placements of the Alinity m
system in hospital labs, academic centers and labs that are
critical to patient care. This test is CE Marked and available in
countries outside the U.S.
The company said the test will allow for fast and efficient
diagnosis and triage of patients who present with respiratory
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
March 05, 2021 09:35 ET (14:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.